-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

622A.O2.6 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Refining The Molecular Roadmap In NHL

Non-Hodgkin Lymphoma: Biology, excluding Therapy Program: Oral and Poster Abstracts
Type: Oral
Saturday, December 5, 2015: 2:00 PM-3:30 PM
W312, Level 3 (Orange County Convention Center)
Moderators:
and Georg Lenz, MD, University of Muenster

Disclosures:
No relevant conflicts of interest to declare.
2:00 PM

Daisuke Ennishi, MD, PhD,1*, Anja Mottok, MD1, Kerry J. Savage, MD MSc1,2, Susana Ben-Neriah1*, Hennady Shulha1*, Pedro Farinha, MD1, Fong Chun Chan, MSc1*, Barbara Meissner1*, Merrill Boyle, BSc1*, Christoffer E Hother, MD, PhD1*, Robert Kridel, MD, MPH1, Ryan Morin, PhD3,4*, Marco A Marra, PhD5, Laurie H. Sehn1, Christian Steidl, MD1, Joseph M. Connors, MD1, David W Scott, MBChB, PhD1 and Randy D. Gascoyne1

1Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada
2British Columbia Cancer Agency, Centre for Lymphoid Cancer and Department of Medical Oncology, Vancouver, BC, Canada
3Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
4Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada
5Canada’s Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada

2:15 PM

Jillian Frances Wise, PhD1*, Sigve Nakken, PhD2*, Daniel Vodak, BS2*, Gunhild Trøen, PhD3*, Ole Christian Lingjærde, PhD4*, Leonardo A. Meza-Zepeda, PhD2*, Ola Myklebost, PhD2*, Klaus Beiske, MD, PhD3*, June Helen Myklebust, PhD1*, Eivind Hovig, PhD2*, Erlend Smeland, MD, PhD1* and Harald Holte Jr., MD, PhD5

1Cancer Immunology, Oslo University Hospital, Oslo, Norway
2Tumor Biology, Oslo University Hospital, Oslo, Norway
3Pathology, Oslo University Hospital, Oslo, Norway
4Oslo University, Oslo, Norway
5Dept of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway

2:30 PM

Daisuke Ennishi, MD, PhD,1*, Anja Mottok, MD1, Hennady Shulha1*, Pedro Farinha, MD1, Fong Chun Chan, MSc1*, Barbara Meissner1*, Merrill Boyle, BSc1*, Susana Ben-Neriah1*, Christoffer E Hother, MD, PhD1*, Robert Kridel, MD, MPH1, Ryan Morin, PhD2,3*, Marco A Marra, PhD4, Kerry J. Savage, MD MSc5, Laurie H. Sehn1, Joseph M. Connors, MD1, Christian Steidl, MD1, David W Scott, MBChB, PhD1 and Randy D. Gascoyne1

1Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada
2Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada
3Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada
4Canada’s Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada
5British Columbia Cancer Agency, Centre for Lymphoid Cancer and Department of Medical Oncology, Vancouver, BC, Canada

2:45 PM

Sami N. Malek1, Denzil Bernard2*, Zhang Xiao Ying2*, Luke F. Peterson3, Nisar A. Amin4*, Shaomeng Wang5*, Kamlai Saiya-Cork4*, Mark S. Kaminski6 and Alfred Chang4*

1Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI
2Hematology/Oncology, University of Michigan, Ann Arbor, MI
3Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
4University of Michigan, Ann Arbor, MI
5Hematology/Oncology, University of Michigan, Ann Arbor
6Univ of Michigan Cancer Ctr, Ann Arbor, MI

3:00 PM

Keisuke Kataoka, MD, Ph.D.1*, Yasunobu Nagata, MD, Ph.D.1*, Akira Kitanaka, MD, PhD2, Yuichi Shiraishi, MD, Ph.D.3*, Jun-ichirou Yasunaga, MD, PhD4, Yasushi Totoki5*, Kenichi Chiba, BA3*, Aiko Sato-Otsubo, PhD1*, Shinichi Kotani1*, Masashi Sanada, MD, Ph.D.6*, Hiroko Tanaka, BA3*, Hiromichi Suzuki, MD, PhD1*, Yusuke Sato, MD, PhD1*, Yusuke Shiozawa, MD1*, Tetsuichi Yoshizato, MD1*, Kenichi Yoshida, MD, Ph.D.1*, Hideki Makishima, MD, Ph.D.1, Guangyong Ma4*, Kisato Nosaka, MD. PhD7, Masakatsu Hishizawa, MD, PhD8, Hidehiro Itonaga, MD, PhD9*, Yoshitaka Imaizumi, MD, PhD10*, Wataru Munakata, MD11*, Nakamura Hiromi5*, Natsuko Hama5*, Kotaro Shide, MD, PhD2, Yoko Kubuki2*, Tomonori Hidaka2*, Takuro Kameda2*, Tsuyoshi Nakamaki, MD12, Ken Ishiyama, MD, Ph.D.13, Shuichi Miyawaki, MD14, Kensei Tobinai, MD, PhD15, Yasushi Miyazaki, MD, Ph.D.10, Akifumi Takaori-Kondo, MD, PhD8, Toshiki Watanabe, M.D., Ph.D.16*, Tatsuhiro Shibata5*, Masao Matsuoka, MD, PhD4, Satoru Miyano, MD, Ph.D.3*, Kazuya Shimoda, MD, PhD2 and Seishi Ogawa, MD, Ph.D.1

1Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
3Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
4Laboratory of Virus Control, Institute for Virus Research, Kyoto University, Kyoto, Japan
5Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan
6Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
7Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
8Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
9Department of Hematology, Sasebo City General Hospital, Sasebo, Japan
10Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan
11Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
12Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
13Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
14Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan
15National Cancer Center Hospital, Tokyo, Japan
16Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan

3:15 PM

Florian Scherer, MD1*, David M. Kurtz, MD2, Aaron M. Newman, PhD1*, Henning Stehr, PhD1*, Chih Long Liu, PhD1*, Li Zhou1*, Alexander F.M. Craig1*, Jacob J. Chabon3*, Alexander F. Lovejoy, PhD4*, Daniel M. Klass, PhD5*, Cynthia Glover1*, Robert S. Ohgami, MD, PhD6, Christian A. Kunder, MD, PhD7*, Brendan C. Visser, MD8*, George Poultsides, MD8*, Ronald Levy, MD1, Maximilian Diehn, MD, PhD4* and Ash A. Alizadeh, MD, PhD1

1Department of Medicine, Divisions of Hematology & Oncology, Stanford University Medical Center, Stanford, CA
2Department of Medicine, Divisions of Hematology & Oncology; Department of Bioengineering, Stanford University Medical Center, Stanford, CA
3Institute of Stem Cell Biology, Stanford University, Stanford, CA
4Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA
5Roche, Pleasanton, CA
6Department of Pathology, Stanford University Medical Center, Stanford, CA
7Stanford University Medical Center, Department of Pathology, Stanford, CA
8Department of Surgery, Stanford University Medical Center, Stanford, CA

*signifies non-member of ASH